Search Results 1-10 of 16522 for ������������KA���:ZA31���24������ ���������������������������������

  1. 24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  2. DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma - Mayo Clinic

    This study is being conducted to examine survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with ...

  3. Ratio of 25(OH)D-to-24,25(OH)2D: A new test to confirm 24-hydroxylase (CYP24A1) deficiency as the cause of hypercalcemia - Mayo Clinic

    Researchers found that the ratio of 25(OH)D-to-24,25(OH)2D is necessary to estimate the calculation of vitamin D 24-hydroxylase enzyme activity to confirm ...

  4. Publications - Sujay A. Vora, M.D. - Mayo Clinic

    ... KA. Intraoperative Radiation Therapy (IORT) in ... 24-00665R1) The Lancet Oncology. 2024. Routman DM ... 2024 Mar 12; 24(1):332. View PubMed; Zhang L ...

  5. Breast Imaging Scholarly Activity

    National/Regional 3/26/2018 1/24/2018. Pregnancy ... Presentation - National/Regional n/a 7/24/2017 ... Robinson KA, Kriegshauser JS, Dahiya N, Young SW, Czaplicki ...

  6. Acetaminophen and codeine (oral route) - Mayo Clinic

    Precautions. It is very important that your doctor check your or your child's progress while you are taking this medicine, especially within the first 24 to 72 ...

  7. Publications - Katie A. Young, M.D. - Mayo Clinic

    Young KA, Rodeheffer RJ, Bird JG, Miranda WR ... 2024 Dec 17; 13 (24):e038965 Epub 2024 Dec 14 ... 2022 Oct; 35 (10):1055-1063 Epub 2022 June 24. View ...

  8. Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    Rochester, Minnesota: 24-002915. NCT ID: NCT06940297. Sponsor Protocol Number: MC240801. About this study. This phase II trial tests how well giving dasatinib ...

  9. A Trial of the Effectiveness, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4) - Mayo Clinic

    ... 24 visit. Males (as assigned at birth) must fulfill the following criteria ... difficile-related diarrhea within 8 weeks after receiving CP101 or placebo in Part ...

  10. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...